Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 8/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1865287 | 1.00 | GCK (0.52) | GCKKCNH2ALDH1A1L3MBTL1EPHX2 | |
| SCHEMBL21820635 | 0.88 | GCK (0.66) | GCKKCNH2TBXA2RPTGDR | |
| SCHEMBL1860360 | 0.88 | GCK (0.66) | GCKKCNH2TBXA2RPTGDR | |
| SCHEMBL1862618 | 0.88 | GCK (0.66) | GCKKCNH2TBXA2RPTGDR | |
| SCHEMBL1862621 | 0.88 | GCK (0.66) | GCKKCNH2TBXA2RPTGDR | |
| SCHEMBL1860363 | 0.88 | GCK (0.66) | GCKKCNH2TBXA2RPTGDR | |
| SCHEMBL2642209 | 0.88 | GCK (0.66) | GCKKCNH2TBXA2RPTGDR | |
| SCHEMBL1861379 | 0.85 | KCNH2 (0.48) | GCKKCNH2ALDH1A1L3MBTL1EPHX2 | |
| SCHEMBL1868718 | 0.85 | KCNH2 (0.46) | GCKKCNH2ALDH1A1L3MBTL1 | |
| SCHEMBL1868719 | 0.85 | KCNH2 (0.46) | GCKKCNH2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2261216-A2 | Pyrazoles as glucokinase activators | F. Hoffmann-La Roche AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| CN-101541756-A | Pyrazoles as glucokinase activators | HOFFMANN LA ROCHE (CH) | 2009-09-23 | — | — | CN | disclosed |
| EP-2046755-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. Hoffmann-Roche AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008012227-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-31 | — | — | WO | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | GCK 2/4885KCNH2 2241/4885ALDH1A1 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.